Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - valganciclovir hydrochloride - oral tablet - 450mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; xanthan gum; allura red ac aluminium lake; polyvinyl alcohol; lecithin; indigo carmine aluminium lake - the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). ,the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; stearic acid; crospovidone; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; xanthan gum; allura red ac aluminium lake; polyvinyl alcohol; lecithin; indigo carmine aluminium lake - the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). ,the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

max health limited - valganciclovir hydrochloride 496.286mg equivalent to to valganciclovir 450mg - film coated tablet - 450 mg - active: valganciclovir hydrochloride 496.286mg equivalent to to valganciclovir 450mg excipient: crospovidone microcrystalline cellulose povidone purified water   sheffield pink 1052 stearic acid - indicated for · treatment of cytomegalovirus (cmv) retinitis in acquired immunodeficiency syndrome (aids) patients. · prevention of cmv disease in solid organ transplant patients at risk.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: povidone; stearic acid; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000; iron oxide red - cipla valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,cipla valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Yhdysvallat - englanti - NLM (National Library of Medicine)

actavis pharma, inc. - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 50 mg in 1 ml - prevention of cmv disease: valganciclovir is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)] . valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1)]. risk summary after oral administration, valganciclovir (prodrug) is converted to ganciclovir (active drug) and, therefore, valganciclovir is expected to have reproductive toxicity effects similar to ganciclovir. in animal studies, ganciclovir caused maternal and fetal toxicity and embryo-fetal mortality in pregnant mice and rabbits as well as teratogenicity in rabbits at exposures two-times the human exposure. there are no available human data on use of valganciclovir or ganciclovir in pregnant women to e

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: silicon dioxide; stearic acid; crospovidone; croscarmellose sodium; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: povidone; silicon dioxide; microcrystalline cellulose; croscarmellose sodium; crospovidone; stearic acid; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: stearic acid; microcrystalline cellulose; povidone; croscarmellose sodium; silicon dioxide; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -